期刊
BIOCHEMICAL SOCIETY TRANSACTIONS
卷 40, 期 -, 页码 31-36出版社
PORTLAND PRESS LTD
DOI: 10.1042/BST20110608
关键词
autotaxin; cancer; drug discovery; lysophosphatidic acid (LPA); 4-pentadecylbenzylphosphonic acid (4-PBA); therapy
资金
- National Institutes of Health [CA092160]
- Grants-in-Aid for Scientific Research [22790203] Funding Source: KAKEN
LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate IPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据